Targeting diastolic dysfunction by genetic engineering of calcium handling proteins.
Publication/Presentation Date
2-1-2003
Abstract
Diastolic heart failure (HF) is associated with significant morbidity and mortality, and is a growing medical problem in this country. Diastolic dysfunction is defined as an abnormality in myocardial relaxation that impairs filling during diastole and contributes to the clinical syndrome of HF. Effective clinical strategies to treat diastolic dysfunction are limited. This article focuses on the potential application of parvalbumin--a fast skeletal muscle calcium buffer--for remediation of slow relaxation in the failing heart.
Volume
13
Issue
2
First Page
63
Last Page
67
ISSN
1050-1738
Published In/Presented At
Coutu, P., Hirsch, J. C., Szatkowski, M. L., & Metzger, J. M. (2003). Targeting diastolic dysfunction by genetic engineering of calcium handling proteins. Trends in cardiovascular medicine, 13(2), 63–67. https://doi.org/10.1016/s1050-1738(02)00213-x
Disciplines
Medicine and Health Sciences | Pediatrics
PubMedID
12586441
Department(s)
Department of Pediatrics
Document Type
Article